Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone1,2Gazyva/Gazyvaro is the only anti-CD20 antibody to ...

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR ...

Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro's superiority over standard therapy alone1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to ...

"I've never asked, 'Why me?.' This is the summit that God gave me, for whatever reason it is. I have to push through it and ...

Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year -- Second pivotal development ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Efficacy of tirzepatide does not differ significantly between men and women, despite sex-specific differences in ...

Novo Nordisk's Alzheimer's trial really is like a lottery ticket. If it wins, the company gains a transformational new market ...

When EMTs respond to my 911 call, my husband is sitting in his recliner sipping coffee. They assess a calm but clueless Bruce ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.

Once-daily oral GLP-1 drug orforglipron leads to significant, dose-dependent weight loss and metabolic benefits without diabetes.